ClinicalTrials.gg
RecruitingNCT06560697SABRVICALUpdated Oct 7, 2025

Cervical Boost by Ablative Stereotactic Radiotherapy (SABR) vs Brachytherapy in Patients With Cervical Carcinoma

An interventional study of SABR VS Intracavitary 3D Brachytherapy in Uterine Cervical Neoplasm, sponsored by National Institute of Cancerología. Recruiting at 1 site in Mexico. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-07.

Sponsored by National Institute of Cancerología · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Uterine Cervical Neoplasms by National Institute of Cancerología — 8 open to participants now, 8 under way, 1 of them phase 3. Uterine Cervical Neoplasms · National Institute of Cancerología.

Planned enrollment
8th of 15
84 · median 84
Started
2024
the only one that year
No phase
8 of 18
5 open now
Registered
18th of 18
by date

Among the 18 studies in Uterine Cervical Neoplasms by National Institute of Cancerología, this one is the 8th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2024, is one of 8 with no phase, and was the 18th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

8 of the 18 studies in Uterine Cervical Neoplasms by National Institute of Cancerología are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Uterine Cervical Neoplasms by National Institute of Cancerología, or all of them as a file.
02

Study summary

Background Cervical cancer (CaCu) is the fourth cause of death in women. In patients with locally advanced disease, the treatment of choice is CT/RT, followed by additional boosting with brachytherapy (BT). There is an international decrease in the use of this technique due to financial restrictions. Given the difficulties in using brachytherapy as a boost, several series have described promising results in local control using boost with highly conformal techniques such as stereotactic body radiotherapy (SBRT). On the other hand, prospective studies are scarce and with controversial results. No study has been published that directly compares three-dimensional intracavitary SBRT and BT. In this clinical trial, the researchers aim to demonstrate that boosting with SBRT is not inferior to intracavitary brachytherapy in patients with CC.

Methodology

Primary Objective:

To evaluate the safety and efficacy of concomitant CT/RT followed by Ablative Body Stereotactic Radiotherapy (SBRT) vs Brachytherapy in patients with Cervical Cancer in clinical stage IB3-IIIC1 at INCan.

Secondary Objectives:

The purpose of this study is to evaluate quality of life, local efficacy (local control and time to local recurrence), overall survival, disease-free survival, and time to distant recurrence.

Study Design:

SABRVICAL is a meticulously designed randomized two-arm open-label phase II study to compare QT/RT + SBRT vs QT/RT + Brachytherapy. It will include patients with IB3-IIIC1 CaCu >18 years of age with adequate renal function. They will be randomized 1:1 to the experimental arm or the standard arm.

Expected Results and Outlook With this study, we aim to assess that the safety and efficacy of concomitant QT/RT with cisplatin followed by SBRT is not inferior to boost with brachytherapy in patients with CaCu IB3-IIIC1. The potential impact of this study is significant, as it could provide new treatment options for hospitals that do not have brachytherapy or have a prolonged waiting list for this procedure.

Read the detailed description

A randomized phase 2 trial is required for two reasons:

  1. The literature lacks enough prospective information. In this context, a randomized phase 2 study would identify SBRT as a promising experimental treatment that, depending on the results, could be tested in a phase 3 trial.
  2. Randomization will provide an adequate control group to serve as a comparator for the experimental arm since non-randomized historical or contemporary controls are not appropriate due to the amount of bias they introduce in patient selection as well as confounders (use of 2D brachytherapy). instead of 3D or the use of conformal radiotherapy and not intensity-modulated radiotherapy).

To evaluate the safety and efficacy of concomitant CT/RT followed by SBRT vs high rate 3D Intracavity Brachytherapy in patients with Cervical Cancer in clinical stage IB3-IIIC1 at INCan:

  1. Evaluate the safety of CT/RT using the CTCAE V5.0 criteria.
  2. Evaluate local efficacy and objective response using the RECIST 1.1 criteria.
  3. Compare the time to local, regional, and distant recurrence between radiotherapy techniques.
  4. Compare overall survival and progression-free survival between both radiotherapy techniques.
  5. Measure the patient's quality of life using the QLQ-C30 and QLQ-CX24 questionnaires.

Randomized open-label phase 2 study in people with CaCu clinical stages IB3-IIIC1 treated with QT/RT. Subjects will be randomized to cervical boost with SBRT or 3D intracavitary brachytherapy in a 1:1 ratio and stratified by nodal status.

Arm 1 will be the experimental arm and will consist of patients with CC clinical stages IB3-IIIC1 who will be treated with CT/RT with a minimum dose of 45Gy and boost in the case of macroscopic nodes (1.8Gy per fraction from Monday to Friday) with cisplatin and cervical boost with SBRT of 28Gy in 4 fractions administered at least every 40 hours to achieve an EQD210(Gy) at PTV D90% of 83.9Gy. Arm 2 will be the control arm that will consist of patients with CC clinical stages IB3-IIIC1 and will be treated with CT/RT with a minimum dose of 45Gy and boost in the case of macroscopic nodes (1.8Gy per fraction from Monday to Friday) with cisplatin and cervical boost with high-dose-rate 3D brachytherapy with a dose of 28Gy in 4 fractions administered at least every 40 hours to achieve an EQD210(Gy) at point A of 83.9Gy.

Sample size The maximum acceptable toxicity (grade 3 or higher) is 24%. The only phase II clinical trial published in the literature about SBRT in CC reported late toxicity of 26.7% at 2 years. For intracavitary brachytherapy, a grade 3 late toxicity of 3.31% has been reported.

The sample size was calculated using a formula for 2 proportions, in which an incidence of grade 3-4 toxicity of 26.7% for arm A and 3.31% for group B was considered. A α error of 5% and a power of 80%. A total of 35 patients for each arm are needed plus a 20% loss = 42 patients for each arm (see figure attached).

Inclusion criteria

  1. People with cervical cancer >18 years of age.
  2. Signed informed consent form approved by the regulatory committees of both institutes and, obtained before each procedure related to the protocol, and that is not considered part of the normal care of the patient.
  3. Able to comply with scheduled visits, treatment schedules, laboratory and imaging studies, and completing quality of life questionnaires.
  4. Histological confirmation of CaCu and staged as IB3-IIIC1.
  5. Squamous cell, adenosquamous, or adenocarcinoma histology.
  6. No prior treatment for cervical cancer.
  7. With disease measurable by CT, MRI, or PET/CT according to REC 1.1 criteria. This measurement must be carried out 28 days before randomization.
  8. Functional status of 0-2 according to WHO criteria.
  9. Charlson Comorbidity Index of 1-4
  10. Candidates to receive cisplatin.
  11. Normal hematological, kidney, and hepatic function according to:

    Hematological:

    Hemoglobin equal to or >10g/L. (With the possibility of transfusion prior to treatment to reach this hemoglobin level).

    Leukocytes >4000/mm3. Platelets>100,000mm3. Neutrophils >1500 / μL

    Hepatic:

    Total bilirubin \<1.5 X times the normal value. Transaminases \<1.5 X times the normal value.

    Renal:

    Creatinine \<1.3mg/dl or creatinine clearance > 40 mL/minute (using the Cockcroft/Gault formula).

    Women: DepCr = (140 - Age in years) x Weight in kg x 0.85

    ___________________________________ 72 x Serum Creatinine in mg/dL Men: DepCr = (140 - Age in years) x Weight in kg x 1.00

    _____________________________________ 72 x Serum Creatinine in mg/dL

  12. Chest tomography without metastatic disease or infectious diseases.
  13. Negative pregnancy test in women of childbearing age.
  14. Not a candidate for another clinical trial within the institution.

Exclusion Criteria

  1. Patients with small-cell carcinoma or other rare histologies (glassy cell carcinoma, melanoma, sarcomas, lymphomas)
  2. Patients with non-measurable disease.
  3. Patients in whom pregnancy is confirmed during the recruitment procedure.
  4. Clinical stages IIIC2-IVB.
  5. Serious infections or diseases that can be reactivated with the use of chemotherapy or that could limit its use (hepatitis or HIV).
  6. Pre-existing neuropathy of any etiology.
  7. Concomitant treatment with another experimental drug.
  8. Mental illnesses: With the intention of maximizing adherence to the study, those patients who are at risk of imminent physical aggression (evident during the interview), have intellectual disabilities or autism, and who come for consultation due to coercion will not be included in the study. their accompanying Severe major depressive disorder, with or without psychotic symptoms; patients in whom a psychiatric diagnosis coexists in addition to the abuse of some recreational substance, eating disorders, schizophrenia, or Bipolar-type Schizoaffective Disorder.
  9. Grade 3 obesity with body mass index >40kg/m2 according to the World Health Organization: Patients treated with pelvic radiotherapy and a body mass index >40kg/m2 are associated with a decrease in quality of life due to sexual, intestinal, genitourinary alterations, as well as greater toxicity due to oncological treatments offered such as intracavitary brachyter in which the positioning of the equipment in the vaginal area is significantly difficult in sedated patients. Patients with grade III obesity will not be included.
  10. Any patient who is absent from follow-up for 5 subsequent appointments will be excluded from the study.
  11. History of total or partial hysterectomy.
  12. Patients with a history of neoadjuvant chemotherapy or use of another antineoplastic drug differ from cisplatin (40 mg/m2).
  13. History of use of Bevacizumab to manage a pathology other than CC or intention to use this drug as part of the treatment of CC.

15. Charlson Comorbidity Index >5 16. Synchronous Cancer except non-melanoma Skin Cancer. 17. History of pelvic irradiation for metachronous cancer. 18. Inflammatory bowel disease or collagen diseases. 19. Patients with severe immunosuppression (transplant or treatment with immunosuppressive drugs).

20. Patients who do not sign the informed consent form. 21. Suspected alcohol or recreational drug abuse. 22. Participation in any other clinical trial in the last 90 days prior to protocol recruitment.

23. Any illness or disability not covered by the exclusion criteria that, in the researchers' opinion, may put the patient's safety and compliance with the protocol at risk.

24. Patients with a percentage of rectal circumference receiving a dose of 15Gy >62.7%.

Elimination Criteria

A patient will be removed from the study for the following reasons:

  1. If the patient requests it.
  2. Inappropriate inclusion in the study without following the inclusion and exclusion criteria.
03

Conditions studied

  • Uterine Cervical Neoplasm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. People with cervical cancer >18 years of age.
  2. Signed form approved by the regulatory committees of both institutes and, obtained before each procedure related to the protocol, and that is not considered part of the normal care of the patient.
  3. Able to comply with scheduled visits, treatment schedules, laboratory and imaging studies, and completing quality of life questionnaires.
  4. Histological confirmation of CaCu and staged as IB3-IIIC1.
  5. Squamous cell, adenosquamous, or adenocarcinoma histology.
  6. No prior treatment for cervical cancer.
  7. With disease measurable by CT, MRI, or PET/CT according to REC 1.1 criteria. This measurement must be carried out 28 days before randomization.
  8. Functional status of 0-2 according to WHO criteria.
  9. Charlson Comorbidity Index of 1-4
  10. Candidates to receive cisplatin.
  11. Normal hematological, kidney, and hepatic function according to:

    Hematological:

    equal to or >10g/L. (With the possibility of transfusion prior to treatment to reach this hemoglobin level).

    Leukocytes >4000/mm3. >100,000mm3. Neutrophils >1500 / μL

    Hepatic:

    Total \<1.5 X times the normal value. Transaminases \<1.5 X times the normal value.

    Renal:

    Creatinine \<1.3mg/dl or > 40 mL/minute (using the Cockcroft/Gault formula).

    Women: DepCr = (140 - Age in years) x Weight in kg x 0.85

    ___________________________________ 72 x Serum Creatinine in mg/dL Men: DepCr = (140 - Age in years) x Weight in kg x 1.00

    _____________________________________ 72 x Serum Creatinine in mg/dL

  12. Chest tomography without disease or infectious diseases.
  13. Negative pregnancy test in women of childbearing age.
  14. Not a candidate for another clinical trial within the institution.

Exclusion criteria

Exclusion Criteria:

  1. Patients with small-cell carcinoma or other rare histologies (glassy cell carcinoma, melanoma, sarcomas, lymphomas)
  2. Patients with non-.
  3. Patients in whom pregnancy is confirmed during the recruitment procedure.
  4. Clinical stages IIIC2-IVB.
  5. Serious infections or diseases that can be reactivated with the use of chemotherapy or that could limit its use (hepatitis or ).
  6. Pre-existing neuropathy of any etiology.
  7. Concomitant treatment with another experimental drug.
  8. Mental illnesses: With the intention of maximizing adherence to the study, those patients who are at risk of imminent physical aggression (evident during the interview), have intellectual disabilities or autism, and who come for consultation due to coercion will not be included in the study. their accompanying Severe major depressive disorder, with or without psychotic symptoms; patients in whom a psychiatric diagnosis coexists in addition to the abuse of some recreational substance, eating disorders, schizophrenia, or Bipolar-type Schizoaffective Disorder.
  9. Grade 3 obesity with >40kg/m2 according to the World Health Organization: Patients treated with pelvic radiotherapy and a body mass index >40kg/m2 are associated with a decrease in quality of life due to sexual, intestinal, genitourinary alterations, as well as greater toxicity due to oncological treatments offered such as intracavitary brachyter in which the positioning of the equipment in the vaginal area is significantly difficult in sedated patients. Patients with grade III obesity will not be included.
  10. Any patient who is absent from follow-up for 5 subsequent appointments will be excluded from the study.
  11. History of total or partial hysterectomy.
  12. Patients with a history of chemotherapy or use of another antineoplastic drug differ from cisplatin (40 mg/m2).
  13. History of use of Bevacizumab to manage a pathology other than CC or intention to use this drug as part of the treatment of CC.

15. Charlson Comorbidity Index >5 16. Synchronous Cancer except non-melanoma Skin Cancer. 17. History of pelvic irradiation for metachronous cancer. 18. Inflammatory bowel disease or collagen diseases. 19. Patients with severe (transplant or treatment with immunosuppressive drugs).

20. Patients who do not sign the form. 21. Suspected alcohol or recreational drug abuse. 22. Participation in any other clinical trial in the last 90 days prior to protocol recruitment.

23. Any illness or disability not covered by the exclusion criteria that, in the researchers' opinion, may put the patient's safety and compliance with the protocol at risk.

24. Patients with a percentage of rectal circumference receiving a dose of 15Gy >62.7%

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Cervical Boost with SABR

    patients with CC clinical stages IB3-IIIC1 who will be treated with CT/RT with a minimum dose of 45Gy and boost in the case of macroscopic nodes (1.8Gy per fraction from Monday to Friday) with cisplatin and cervical boost with SBRT of 28Gy in 4 fractions administered at least every 40 hours to achieve an EQD210(Gy) at PTV D90% of 83.9Gy

    Radiation: SABR VS Intracavitary 3D Brachytherapy

  • Active comparator
    Cervical Boost with Intracavitary Brachytherapy

    Patients with CC clinical stages IB3-IIIC1 will be treated with CT/RT with a minimum dose of 45Gy and boost in the case of macroscopic nodes (1.8Gy per fraction from Monday to Friday) with cisplatin and cervical boost with high-dose-rate 3D brachytherapy with a dose of 28Gy in 4 fractions administered at least every 40 hours to achieve an EQD210(Gy) at point A of 83.9Gy.

    Radiation: SABR VS Intracavitary 3D Brachytherapy

Interventions

  • RadiationSABR VS Intracavitary 3D Brachytherapy

    Arm 1 will be the experimental arm and will consist of patients with CC clinical stages IB3-IIIC1 who will be treated with CT/RT with a minimum dose of 45Gy and boost in the case of macroscopic nodes (1.8Gy per fraction from Monday to Friday) with cisplatin and cervical boost with SBRT of 28Gy in 4 fractions administered at least every 40 hours to achieve an EQD210(Gy) at PTV D90% of 83.9Gy. Arm 2 will be the control arm that will consist of patients with CC clinical stages IB3-IIIC1 and will be treated with CT/RT with a minimum dose of 45Gy and boost in the case of macroscopic nodes (1.8Gy per fraction from Monday to Friday) with cisplatin and cervical boost with high-dose-rate 3D brachytherapy with a dose of 28Gy in 4 fractions administered at least every 40 hours to achieve an EQD210(Gy) at point A of 83.9Gy.

06

What researchers measure

Primary outcomes

  1. Acute Toxicity

    It will be measured using the CTCAE V5.0 criteria.

    Time frame: 5 years

  2. Chronic Toxicity

    It will be measured using the CTCAE V5.0 criteria.

    Time frame: 5 years

Secondary outcomes

  1. General Health Perception

    Quality of Life measured with the QLQ-C30 and QLQ-CX24 questionnaires validated in Mexican patients.

    Time frame: 5 years

  2. Local Control

    Local efficacy and objective response using the RECIST 1.1 criteria.

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2027, 43 months after the start.

Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 43 months is above that.

Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2024
First posted
Aug 19, 2024
StartActual
May 15, 2024
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2030
Last update
Oct 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06560697
Lead sponsor
National Institute of Cancerología
Collaborators
National Institute of Medical Sciences and Nutrition, Salvador Zubiran
Responsible party
Sponsor
First posted
Aug 19, 2024
Start date
May 15, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Oct 7, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion